Extravasation reactions associated with the administration of pamidronate: 11 cases (2008-2013).

B A Marker,L G Barber,C A Clifford, S S Correa, P L Thalhofer, T A LaDue,C M Mullin, M L Sauerbrey,C C Wood

VETERINARY AND COMPARATIVE ONCOLOGY(2017)

引用 4|浏览21
暂无评分
摘要
Pamidronate is a bisphosphonate drug widely utilized in veterinary oncologic practice for the palliation of malignant osteolysis. Pamidronate has not been previously reported to cause tissue injury upon extravasation in dogs. The medical records of 11 client-owned dogs undergoing palliative treatment for primary bone tumors with known or suspected pamidronate extravasation reactions were reviewed. The majority of adverse events were low grade in nature, however in some cases, the reactions were severe and led to euthanasia in one instance. Time to complete resolution of lesions ranged from within several days to greater than one and a half months. Aside from the dog that was euthanized, no long-term sequelae of extravasation were identified. Treatments employed to address the reactions varied widely. Pamidronate extravasation reaction appears to be an uncommon, but potentially serious complication of intravenous administration.
更多
查看译文
关键词
comparative oncology,oncology,small animal,small animal internal medicine,supportive care
AI 理解论文
溯源树
样例
生成溯源树,研究论文发展脉络
Chat Paper
正在生成论文摘要